Raycome Health Completes RMB 55 Million Series B+ Financing to Build Comprehensive Medical and Health Ecosystem

Shenzhen Raycome Health Technology Co., Ltd. (hereinafter referred to as “Raycome Health”) recently completed a B+ round of financing amounting to RMB 55 million, led by Oriental Fortune Capital. According to the head of Raycome Health, the funds will be allocated to four key areas: online operations, offline marketing, international trade expansion, and the Internet-plus blood pressure management system, with the aim of comprehensively building a healthcare ecosystem.

In 2008, Raycome Health was established in the Science and Technology Park of Nanshan District, Shenzhen. It is a national high-tech comprehensive medical device manufacturer engaged in the research and development, production, and sales of medical devices, as well as chronic disease health management. The company boasts a scientific research team led by Dr. Wu Xiaoguang, a renowned laser research expert and Ph.D. graduate from Tsinghua University. This team provides robust technical support for the independent research, development, and upgrading of its products.

The company’s independently developed next-generation precision blood pressure measurement technology—Pulse Wave Blood Pressure Measurement, featuring dual tubes, dual airbags, and dual sensors—achieves a measurement accuracy of ±2 mmHg. It has been granted invention patents in nine countries and regions, including China, South Korea, Japan, and Russia.and globallyPatent applications have been filed in over 40 countries. The pulse wave blood pressure measurement method has undergone clinical validation at more than 20 large Grade A tertiary hospitals, including Beijing Fuwai Hospital and the Affiliated Hospital of Tongji Medical College, Huazhong University of Science and Technology.

Invention Patent for Pulse Wave Blood Pressure Measurement Method

Pulse Wave blood pressure monitors have served over 10,000 medical institutions and have been successively designated as the specified blood pressure measurement equipment by the China Hypertension League, the National Center for Cardiovascular Diseases, and the National Joint Laboratory for Hypertension Big Data. In 2016, Pulse Wave blood pressure monitors were supplied to the Logistics Support Department of the Chinese People's Liberation Army. In 2019, Pulse Wave blood pressure monitors were officially included in the national central emergency reserves, managed and allocated by relevant state authorities, to provide medical device assistance for post-disaster recovery, emergency situations, and social rescue operations. Also in 2019, Pulse Wave’s tunnel-type blood pressure monitors, office blood pressure monitors, ambulatory blood pressure monitors, and family doctor electronic blood pressure monitors were designated as the specified suppliers for the National Hypertension Specialized Medical Consortium.

Raycome Health is the world’s only provider of fully integrated hardware and software solutions for comprehensive blood pressure management. Its PulseWave electronic blood pressure monitors rank first among domestic brands in market share within hospital channels. In niche segments such as all-in-one health kiosks, smart healthcare, and hemodialysis, PulseWave blood pressure monitors hold a commanding lead in market share. With the acceleration of medical device localization in China and the advancement of the “Mercury Elimination Campaign,” the company’s related products are poised to maintain rapid growth in hospital channels.

Pulse Wave Medical Ambulatory Blood Pressure Monitor RBP-9001

By leveraging high-dimensional strategies to penetrate lower-dimensional markets, the company’s reputation and radiating influence in the medical sector are comprehensively driving traffic to the consumer-facing (C-end) market, with sales already showing an accelerating growth trend. In an era where consumer traffic is paramount, Raycome Health has created blockbuster product combinations, expanded its product portfolio, and diversified its categories, achieving explosive growth across all online platforms for end consumers. Sales volume is expected to maintain exponential growth. With the implementation of the company’s international trade strategy, global layout of pulse wave invention patents, acquisition of international certifications such as CE, AAMI, BHS, and ESH, and the establishment of a channel-centric national agency system, the company has signed agency agreements in over ten countries.

Internet+ Blood Pressure Management System

Leveraging precision big data, mobile healthcare, and artificial intelligence technologies in pulse wave blood pressure monitors, the company is dedicated to developing an "Internet Plus" blood pressure management system. It provides customers with comprehensive services, including self-service blood pressure screening, ambulatory blood pressure monitoring, statistical analysis of home blood pressure monitoring data, health alerts, and healthy lifestyle guidance, thereby creating a medical-health ecosystem that encompasses the entire industry chain of R&D, manufacturing, and technological application of blood pressure measurement devices. By deeply cultivating blood pressure health management and empowering the "Healthy China" initiative, the company offers effective support for the prevention, treatment, and management of chronic diseases. Committed to focusing on blood pressure health, it continuously contributes to human well-being. Building on a core focus on blood pressure products, the company optimizes its product portfolio under the Medical Device Registrant System, fosters a new multi-dimensional model for home medical healthcare, and strategically establishes a holistic ecosystem across the entire big health industry chain.

Shenzhen Oriental Fortune Capital Co., Ltd. (hereinafter referred to as “OFC”) is a professional venture capital management firm founded by several industry veterans with extensive experience, proven track records, and significant influence in China’s venture capital sector. OFC is committed to investing in target companies with high growth potential and IPO prospects, actively providing value-added services to portfolio companies to enhance their profitability, and striving to help them maximize enterprise value through pathways such as initial public offerings (IPOs), thereby delivering satisfactory capital appreciation returns to investors.

Behind Oriental Fortune Capital’s strategic move lies the vast development potential in the niche field of blood pressure management. Statistics show that there are 330 million adults with hypertension in China, meaning one in every four adults suffers from this condition. The direct economic burden of hypertension accounts for 6.6% of China’s total health expenditure. Driven by urgent domestic demand, the field of blood pressure health management is poised for significant growth.